Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 °C hyperthermia

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Cancer Letters

• Publication date

  1995-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0304-3835(95)90158-2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytokine Induction in Humans by 41.8 °C WholeBody Hyperthermia

  1993cited by this paper
• Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.

  1992cited by this paper
• Biologic Therapy of Cancer

  1992cited by this paper
• Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy.

  1992cited by this paper
• Role of poly(ADP-ribose) formation in DNA repair

  1992cited by this paper
• High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

  1992cited by this paper
• Whole Body Hyperthermia: Biological and Clinical Aspects

  1992cited by this paper
• Effect of hyperthermia in vitro and in vivo on adenine and pyridine nucleotide pools in human peripheral lymphocytes

  1991cited by this paper
• Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations.

  1990cited by this paper
• Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion

  1989cited by this paper
• Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.

  1989cited by this paper
• Interactions of thymidine, hyperthermia, and cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in human T-cell leukemia.

  1989cited by this paper
• Neutral red uptake and clonogenic survival assays of the hyperthermic sensitization of tumor cells to tumor necrosis factor.

  1989cited by this paper
• Tumor necrosis factor-mediated cytotoxicity involves ADP-ribosylation.

  1988cited by this paper
• Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.

  1988cited by this paper
• ADP-Ribosylation of Proteins

  1987cited by this paper
• Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II.

  1987cited by this paper
• Hyperthermic Enhancement of cis-Diammine-1,1-cyclobutane Dicarboxylate Platinum(II) Cytotoxicity in Human Leukemia Cells in Vitro

  1987cited by this paper
• Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells.

  1987cited by this paper
• Thermochemotherapy with cis-platinum, CCNU, BCNU, chlorambucil and melphalan on murine marrow and two tumours: therapeutic gain for melphalan only.

  1985cited by this paper
• Potentiation of melphalan by systemic hyperthermia in mice: therapeutic gain for mouse lung microtumours.

  1985cited by this paper
• Effects of cytostatic drugs and 40.5 degrees C hyperthermia on human bone marrow progenitors (CFU-C) and human clonogenic tumor cells implanted into mice.

  1985cited by this paper
• Poly(ADP-ribose) in the cellular response to DNA damage.

  1985cited by this paper
• A Prospective Randomized Study of Regional Extremity Perfusion in Patients with Malignant Melanoma

  1984cited by this paper
• Whole body hyperthermia (41–42 °C): A simple technique for unanesthetized mice

  1984cited by this paper
• Experimental Design: Review and Comment

  1984cited by this paper
• Hyperthermia and Cancer

  1982cited by this paper
• The effect of hyperthermia and melphalan on survival of human fibroblast strains and melanoma cell lines.

  1977cited by this paper

• Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study.

  2024cites this paper
• Oncological outcome after hyperthermic isolated limb perfusion for primarily unresectable versus locally recurrent soft tissue sarcoma of extremities.

  2020cites this paper
• Heat Shock Protein translocation induced by membrane fluidization increases tumor-cell sensitivity to chemotherapeutic drugs.

  2010cites this paper
• Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).

  2009cites this paper
• Revolutionizing the treatment of locally advanced extremity soft tissue sarcomas: a review on TNFα-based isolated limb perfusion

  2009cites this paper
• Artificial cytokine storm combined with hyperthermia induces significant anti-tumor effect in mice inoculated with Lewis lung carcinoma and B16 melanoma cells

  2006cites this paper
• Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor

  2006influential citation
• Hyperthermia and immunity. A brief overview.

  2006cites this paper
• Effects of Local and Whole Body Hyperthermia on Immunity

  2006cites this paper
• Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas

  2005cites this paper
• Docetaxel and hyperthermia: Factors that modify thermal enhancement

  2004cites this paper
• Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases

  2004cites this paper
• TNF&agr;-Based Isolated Perfusion for Limb-Threatening Soft Tissue Sarcomas: State of the Art and Future Trends

  2003cites this paper
• A Systemic Hyperthermia Oncologic Working Group Trial

  2003cites this paper
• Radioprotection by whole body hyperthermia: possible mechanism(s)

  2002cites this paper
• Isolated Limb Perfusion for Malignant Melanoma and Soft Tissue Sarcoma

  2000cites this paper
• Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats

  1999influential citation
• Hyperthermic modulation of SN‐38‐induced topoisomerase I DNA cross‐linking and SN‐38 cytotoxicity through altered topoisomerase I activity

  1999cites this paper
• A pilot study of melphalan, tumor necrosis factor-α and 41.8 °C whole-body hyperthermia

  1999cites this paper
• Isolated Limb Perfusion With High-Dose Tumor Necrosis Factor α and Melphalan for Kaposi Sarcoma

  1999cites this paper
• Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy.

  1999cites this paper
• High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation

  1997cites this paper
• Lack of thermal enhancement for taxanes in vitro.

  1997cites this paper